Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
Abstract Background Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models. However, in immune-desert models, the efficacy of YM101 was limited. Bivalent manganese (Mn2+) is identified as a natural stimu...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-09-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-021-01155-6 |
| _version_ | 1818912401042440192 |
|---|---|
| author | Ming Yi Mengke Niu Jing Zhang Shiyu Li Shuangli Zhu Yongxiang Yan Ning Li Pengfei Zhou Qian Chu Kongming Wu |
| author_facet | Ming Yi Mengke Niu Jing Zhang Shiyu Li Shuangli Zhu Yongxiang Yan Ning Li Pengfei Zhou Qian Chu Kongming Wu |
| author_sort | Ming Yi |
| collection | DOAJ |
| description | Abstract Background Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models. However, in immune-desert models, the efficacy of YM101 was limited. Bivalent manganese (Mn2+) is identified as a natural stimulator of interferon genes (STING) agonist, which might enhance cancer antigen presentation and improve the therapeutic effect of YM101. Methods The effect of Mn2+ on STING pathway was validated by western blotting and enzyme-linked immunosorbent assay. Dendritic cell (DC) maturation was measured by flow cytometry. The synergistic effect between Mn2+ and YM101 in vitro was determined by one-way mixed lymphocyte reaction, CFSE dilution assay, and cytokine detection. The in vivo antitumor effect of Mn2+ plus YM101 therapy was assessed in CT26, EMT-6, H22, and B16 tumor models. Flow cytometry, RNA-seq, and immunofluorescent staining were adopted to investigate the alterations in the tumor microenvironment. Results Mn2+ could activate STING pathway and promote the maturation of human and murine DC. The results of one-way mixed lymphocyte reaction showed that Mn2+ synergized YM101 in T cell activation. Moreover, in multiple syngeneic murine tumor models, Mn2+ plus YM101 therapy exhibited a durable antitumor effect and prolonged the survival of tumor-bearing mice. Relative to YM101 monotherapy and Mn2+ plus anti-PD-L1 therapy, Mn2+ plus YM101 treatment had a more powerful antitumor effect and a broader antitumor spectrum. Mechanistically, Mn2+ plus YM101 strategy simultaneously regulated multiple components in the antitumor immunity and drove the shift from immune-excluded or immune-desert to immune-inflamed tumors. The investigation in the TME indicated Mn2+ plus YM101 strategy activated innate and adaptive immunity, enhanced cancer antigen presentation, and upregulated the density and function of tumor-infiltrating lymphocytes. This normalized TME and reinvigorated antitumor immunity contributed to the superior antitumor effect of the combination therapy. Conclusion Combining Mn2+ with YM101 has a synergistic antitumor effect, effectively controlling tumor growth and prolonging the survival of tumor-bearing mice. This novel cocktail strategy has the potential to be a universal regimen for inflamed and non-inflamed tumors. |
| first_indexed | 2024-12-19T23:14:00Z |
| format | Article |
| id | doaj.art-b104c7920dec4e51bd68b3d727e5f5fe |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-12-19T23:14:00Z |
| publishDate | 2021-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-b104c7920dec4e51bd68b3d727e5f5fe2022-12-21T20:02:09ZengBMCJournal of Hematology & Oncology1756-87222021-09-0114112110.1186/s13045-021-01155-6Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancersMing Yi0Mengke Niu1Jing Zhang2Shiyu Li3Shuangli Zhu4Yongxiang Yan5Ning Li6Pengfei Zhou7Qian Chu8Kongming Wu9Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyWuhan YZY Biopharma Co., LtdDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyWuhan YZY Biopharma Co., LtdDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalWuhan YZY Biopharma Co., LtdDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyAbstract Background Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models. However, in immune-desert models, the efficacy of YM101 was limited. Bivalent manganese (Mn2+) is identified as a natural stimulator of interferon genes (STING) agonist, which might enhance cancer antigen presentation and improve the therapeutic effect of YM101. Methods The effect of Mn2+ on STING pathway was validated by western blotting and enzyme-linked immunosorbent assay. Dendritic cell (DC) maturation was measured by flow cytometry. The synergistic effect between Mn2+ and YM101 in vitro was determined by one-way mixed lymphocyte reaction, CFSE dilution assay, and cytokine detection. The in vivo antitumor effect of Mn2+ plus YM101 therapy was assessed in CT26, EMT-6, H22, and B16 tumor models. Flow cytometry, RNA-seq, and immunofluorescent staining were adopted to investigate the alterations in the tumor microenvironment. Results Mn2+ could activate STING pathway and promote the maturation of human and murine DC. The results of one-way mixed lymphocyte reaction showed that Mn2+ synergized YM101 in T cell activation. Moreover, in multiple syngeneic murine tumor models, Mn2+ plus YM101 therapy exhibited a durable antitumor effect and prolonged the survival of tumor-bearing mice. Relative to YM101 monotherapy and Mn2+ plus anti-PD-L1 therapy, Mn2+ plus YM101 treatment had a more powerful antitumor effect and a broader antitumor spectrum. Mechanistically, Mn2+ plus YM101 strategy simultaneously regulated multiple components in the antitumor immunity and drove the shift from immune-excluded or immune-desert to immune-inflamed tumors. The investigation in the TME indicated Mn2+ plus YM101 strategy activated innate and adaptive immunity, enhanced cancer antigen presentation, and upregulated the density and function of tumor-infiltrating lymphocytes. This normalized TME and reinvigorated antitumor immunity contributed to the superior antitumor effect of the combination therapy. Conclusion Combining Mn2+ with YM101 has a synergistic antitumor effect, effectively controlling tumor growth and prolonging the survival of tumor-bearing mice. This novel cocktail strategy has the potential to be a universal regimen for inflamed and non-inflamed tumors.https://doi.org/10.1186/s13045-021-01155-6The tumor microenvironmentManganesecGAS-STINGPD-L1TGF-βBispecific antibody |
| spellingShingle | Ming Yi Mengke Niu Jing Zhang Shiyu Li Shuangli Zhu Yongxiang Yan Ning Li Pengfei Zhou Qian Chu Kongming Wu Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers Journal of Hematology & Oncology The tumor microenvironment Manganese cGAS-STING PD-L1 TGF-β Bispecific antibody |
| title | Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers |
| title_full | Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers |
| title_fullStr | Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers |
| title_full_unstemmed | Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers |
| title_short | Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers |
| title_sort | combine and conquer manganese synergizing anti tgf β pd l1 bispecific antibody ym101 to overcome immunotherapy resistance in non inflamed cancers |
| topic | The tumor microenvironment Manganese cGAS-STING PD-L1 TGF-β Bispecific antibody |
| url | https://doi.org/10.1186/s13045-021-01155-6 |
| work_keys_str_mv | AT mingyi combineandconquermanganesesynergizingantitgfbpdl1bispecificantibodyym101toovercomeimmunotherapyresistanceinnoninflamedcancers AT mengkeniu combineandconquermanganesesynergizingantitgfbpdl1bispecificantibodyym101toovercomeimmunotherapyresistanceinnoninflamedcancers AT jingzhang combineandconquermanganesesynergizingantitgfbpdl1bispecificantibodyym101toovercomeimmunotherapyresistanceinnoninflamedcancers AT shiyuli combineandconquermanganesesynergizingantitgfbpdl1bispecificantibodyym101toovercomeimmunotherapyresistanceinnoninflamedcancers AT shuanglizhu combineandconquermanganesesynergizingantitgfbpdl1bispecificantibodyym101toovercomeimmunotherapyresistanceinnoninflamedcancers AT yongxiangyan combineandconquermanganesesynergizingantitgfbpdl1bispecificantibodyym101toovercomeimmunotherapyresistanceinnoninflamedcancers AT ningli combineandconquermanganesesynergizingantitgfbpdl1bispecificantibodyym101toovercomeimmunotherapyresistanceinnoninflamedcancers AT pengfeizhou combineandconquermanganesesynergizingantitgfbpdl1bispecificantibodyym101toovercomeimmunotherapyresistanceinnoninflamedcancers AT qianchu combineandconquermanganesesynergizingantitgfbpdl1bispecificantibodyym101toovercomeimmunotherapyresistanceinnoninflamedcancers AT kongmingwu combineandconquermanganesesynergizingantitgfbpdl1bispecificantibodyym101toovercomeimmunotherapyresistanceinnoninflamedcancers |